The size of the Sepsis Diagnostics Market in North America is valued at USD 430.63 Million in 2023. This value is growing at a CAGR of 8.43%, to reach USD 645.43 Million by 2028 owing to factors such as the increase in the geriatric population in the region combined with the development of infrastructure of health care and the Increasing prevalence of cancer and diabetes in the countries of the North American region. However, lack of awareness and shortage of skilled human resources in North American areas limit the growth of the region's sepsis diagnostics market.
Factors such as the increased prevalence of sepsis, increased incidence of hospital-acquired infections, increased numbers of pneumonia cases, increased numbers of sepsis treatments, and studies related to sepsis, and improved activity are expected to accelerate the growth rate of the North American sepsis diagnostics market.
Nosocomial infections and the elevating prevalence of sepsis have led to a growing need for its early diagnosis, one of the North American sepsis diagnostic market drivers. The other significant factors driving growth in the North American sepsis diagnostics market are the increasing prevalence of different bacterial strains resistant to antibiotics, an aging population, increased healthcare awareness, and healthcare spending. Also, the growing number of surgical procedures and the number of product approvals for the diagnosis of sepsis are expected to support the North American sepsis diagnosis market's growth shortly. The high incidence of hospital infections is the main factor accelerating the North American sepsis diagnostic market's growth.
In the United States alone, approximately 1,000,000 deaths are due to sepsis caused by hospital patients. Besides, the development of biomarkers used in clinical trials that possess specificity has significantly boosted business growth. This large number is expected to serve as an engine for market growth. An increase in cases of nosocomial infections acts as a market driver. In addition, the neonatal and geriatric population is more affected by sepsis, which adds to the market's growth rate. Molecular diagnostics is expected to dominate the North American market for sepsis diagnostics by technology during 2023-2028. Technological advancements in molecular diagnostics, coupled with the growing need for rapid and accurate results and clinicians' penchant for molecular diagnostics diagnostic techniques, are expected to drive segment growth through 2028.
According to the North American Hospital Association, postoperative blood infections increased 8%, and urinary tract infections increased by 3.6% with postoperative catheter use. Healthcare providers, nursing teams, and individual physicians and nurses are also aware of infection-related issues and have taken specific steps to prevent them. However, similar hospital infections have been observed around the world, increasing the demand for sepsis diagnosis. As a result, improved nosocomial conditions are expected to drive the North America Sepsis Diagnostics Market's overall growth during the forecast period.
The lack of standard protocols has hindered the growth of the North America Sepsis Diagnostics Market. Dearth in skilled people to operate the systems in diagnostic centers is also degrading the market's demand. The lack of a standard protocol is a significant constraint for the North American market.
The National Institutes of Health supports several studies on sepsis and evaluates various potential treatments for sepsis. The US Centers for Disease Control and Prevention (CDC) has launched the “Getting Rid of Sepsis,” an educational program designed to protect Americans from sepsis. The plan calls on healthcare professionals to educate patients, prevent infections, detect and diagnose sepsis early, and promptly treat sepsis. New technologies, combined with a better understanding of the immune system's response to premature, early-infected neonates, offer the opportunity to develop essential biomarkers to improve the early identification of this high-risk population. As a result, increased sepsis and government initiatives may drive North America Sepsis Diagnostics Market growth.
The skilled technicians for advanced technology are significant challenges in the North America Sepsis Diagnostics Market's growth.
Covid-19 impact on North America Sepsis Diagnostics market:
SARS-CoV-2, a coronavirus human has never encountered before, is responsible for hundreds of thousands of deaths in the North American region. The surfacing of new infectious agents is tragically part of the contagious disease cycle. What is not part of this cycle are the many COVID-19-related deaths that occur due to our systemic inability to use rapid diagnostic tools - something health systems have long neglected at our risk. In addition, many deaths from Covid-19 reflect deaths from sepsis, which can also be largely avoided with better diagnostic tools. Sepsis, the immune system's uncontrolled response to infection, often results in organ failure and death. In the United States alone, sepsis is responsible for more than 250,000 deaths per year and accounts for 1 in 3 deaths in hospitals.
This research report has been segmented and sub-segmented the North America Sepsis Diagnostics Market into the following categories:
Regionally, North America was accounted for most of the market share in the global market in 2022. It can be attributed to the increasing prevalence of sepsis, increasing the incidence of nosocomial infections, and the rapid adoption of sepsis diagnostic devices: high-quality range and growing government support for sepsis research. In addition, high brand awareness, favorable reimbursement scenarios, and the presence of established players facilitate this region's dominance throughout the study period. As a result, North America is the leading regional market for the diagnosis of sepsis, followed by Europe. The presence of prominent players in these two regions is likely to remain an essential factor for the sepsis diagnostics market in these regions during the forecast period.
The U.S. Sepsis Diagnostics Market is leading the North American market while Canada is in second place. Stakeholder focuses on research projects, drug discovery, and diagnosis has helped the USA dominate the market. However, the USA is also expected to increase the fastest owing to several factors such as an increasing number of surgical procedures, a growing number of clinical studies, developing healthcare infrastructure, and the rising focus of global players in this region.
KEY MARKET PLAYERS:
A few of the prominent companies dominating the North America Sepsis Diagnostics market profiled in the report are bioMérieux SA, T2 Biosystem Inc, Cepheid, Thermo Fisher Scientific Inc., Nanosphere Inc, Abbott Laboratories, Roche Diagnostics Limited, Becton, Dickinson and Company, Bruker Corporation, and Beckman Coulter, Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com